131705-80-1

Basic information

• Product Name: 1H-Benzimidazole, 2-chloro-1-[(4-chlorophenyl)methyl]-
• CAS NO: 131705-80-1
• Molecular Formula: C14H10Cl2N2
• Molecular Weight: 277.153
• Mol File: 131705-80-1.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 1H-Benzimidazole, 2-chloro-1-[(4-chlorophenyl)methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole, 2-chloro-1-[(4-chlorophenyl)methyl]-(131705-80-1)
• EPA Substance Registry System: 1H-Benzimidazole, 2-chloro-1-[(4-chlorophenyl)methyl]-(131705-80-1)

Safety Data

• Hazardous Substances Data: 131705-80-1(Hazardous Substances Data)

Upstream product

• 622-95-7 4-chlorobenzyl bromide 
• 5729-18-0 N-(p-Chlorophenylmethyl)-2-amino aniline 
• 5822-16-2 N-(p-Chlorobenzyl)-2-nitro aniline 
• 4857-06-1 2-chloro-1H-benzoimidazole 
• 131705-70-9 N-(p-Chlorophenylmethyl)-2(1H)-benzimidazolone 
• 131705-70-9 1-(p-chlorobenzyl)-2-hydroxy-1H-benzimidazole 
• 615-16-7 1H-benzimidazol-2-ol 
• 104-83-6 1-Chloro-4-(chloromethyl)benzene 

Downstream Products

• 388575-15-3 [10-(4-chloro-benzyl)-3,4-dioxo-3,4-dihydro-10H-benzo[4,5]imidazo[2,1-c][1,2,4]triazin-2-yl]-acetic acid ethyl ester 
• 388575-00-6 10-(4-chloro-benzyl)-2,10-dihydro-benzo[4,5]imidazo[2,1-c][1,2,4]triazine-3,4-dione 
• 100622-93-3 1-(4-chloro-benzyl)-1H-benzoimidazole-2-thiol 

Relevant articles and documents

Design, synthesis and characterization of novel N-heterocyclic-1-benzyl-1H-benzo[d]imidazole-2-amines as selective TRPC5 inhibitors leading to the identification of the selective compound, AC1903

The transient receptor potential cation channel 5 (TRPC5) has been previously shown to affect podocyte survival in the kidney. As such, inhibitors of TRPC5 are interesting candidates for the treatment of chronic kidney disease (CKD). Herein, we report the synthesis and biological characterization of a series of N-heterocyclic-1-benzyl-1H-benzo[d]imidazole-2-amines as selective TRPC5 inhibitors. Work reported here evaluates the benzimidazole scaffold and substituents resulting in the discovery of AC1903, a TRPC5 inhibitor that is active in multiple animal models of CKD.

Heterocyclic Ring and Carbocyclic Derivative

The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect, e.g. a compound of Formula (I): wherein R2 is a hydrogen atom or the like; ring A is five- to seven-cycloalkane or th

MEDICINAL USE OF RECEPTOR LIGANDS

Compounds of formula (I) are ligands of the melanin concentrating hormone-1 receptor (MCH-1 R), useful in the treatment of diseases responsive to modulation of melanin concentrating hormone (MCH) activity, for example feeding disorders and diseases for which obesity is a risk factor (I): wherein ring B is selected from specific substituted phenyl or benz-fused 5-membered N-containing heterocycles defined in the specification; R, is attached to a ring carbon of ring B, and represents hydrogen, F, Cl, or -OCH3; X is =CH- or =N-; L, is -CH2- or -CH2CH2- ; L2 is a bond, -CH2- or -CO-; R2 is H or C,-C3 alkyl, or -N(R2) L,- is selected from specific cyclic amino linker radicals as defined in the specification; ring A is selected from specific N- containing heterocyclic rings as defined in the specification.